EvolveImmune Therapeutics

EvolveImmune Therapeutics develops an immunobiological platform that delivers both sustained immune activation and tumor cell targeting in a single agent. Through integrated signaling, EVs first in category biologics directly target tumor cells and provide potent, tissue-localized amplification of cytokine secretion at the tumor site to maximize tumor killing.

The company's biotherapeutics are engineered to overcome the limitations of conventional CD3 bispecific and other immune therapies to offer a better future for our patients in need, by maximizing therapeutic benefit and minimizing toxicity.

EvolveImmune Therapeutics headquartered in United States, North America, operates in the Biotechnology, Health Care, Medical, Therapeutics, Oncology sector. The company focuses on Biotechnology and has secured $2.2B in funding across 40 round(s). With a team of 11-50 employees, EvolveImmune Therapeutics is actively contributing to advancements in Biotechnology. Their latest funding round, Venture Round - EvolveImmune Therapeutics, raised $37.4M. Discover more about their projects, partnerships, and impact on our platform.